Loading...
XASERVP
Market cap18mUSD
Dec 23, Last price  
0.62USD
1D
-3.13%
1Q
-17.33%
Jan 2017
-33.33%
Name

Retractable Technologies Inc

Chart & Performance

D1W1MN
XASE:RVP chart
P/E
—
P/S
0.43
EPS
—
Div Yield, %
1.25%
Shrs. gr., 5y
-1.73%
Rev. gr., 5y
5.55%
Revenues
44m
-54.02%
21,521,70024,235,01625,324,51926,289,72027,899,31838,981,83736,219,56232,102,29633,644,50330,785,12734,520,63029,552,20029,826,63634,493,83833,274,70241,797,17981,862,453188,382,45494,818,93843,596,926
Net income
-7m
L
54,691,395-1,238,323-3,869,484-6,948,104-9,643,580-9,422,3002,400,6941,418,482-4,132,892-6,213,852-2,354,6054,314,318-3,694,907-3,736,038-1,339,9433,148,23424,223,01356,064,2415,078,557-7,011,036
CFO
3m
-83.50%
56,479,136-2,234,899-3,354,031-4,216,671-5,923,242-12,299,7318,730,6725,513,773158,3372,933,569-3,867,822-3,252,157-794,912-2,922,636-1,195,4952,194,63818,997,02932,793,49916,768,1282,766,848
Earnings
Mar 27, 2025

Profile

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
URL
https://retractable.com/
IPO date
May 04, 2001
Employees
190
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
43,597
-54.02%
94,819
-49.67%
188,382
130.12%
Cost of revenue
55,085
95,672
115,787
Unusual Expense (Income)
NOPBT
(11,488)
(853)
72,595
NOPBT Margin
38.54%
Operating Taxes
(1,905)
84
18,887
Tax Rate
26.02%
NOPAT
(9,583)
(937)
53,709
Net income
(7,011)
-238.05%
5,079
-90.94%
56,064
131.45%
Dividends
(232)
(253)
(3,824)
Dividend yield
0.70%
0.47%
1.61%
Proceeds from repurchase of equity
(1,107)
(8,705)
(6,424)
BB yield
3.33%
16.10%
2.71%
Debt
Debt current
304
286
289
Long-term debt
1,234
1,533
1,814
Deferred revenue
(15,078)
(6,848)
Other long-term liabilities
69,774
75,460
69,996
Net debt
(45,751)
(19,927)
(40,329)
Cash flow
Cash from operating activities
2,767
16,768
32,793
CAPEX
(853)
(16,830)
(58,367)
Cash from investing activities
(10,762)
(31,203)
(63,040)
Cash from financing activities
942
4,993
41,843
FCF
3,376
(13,701)
(13,481)
Balance
Cash
47,289
49,379
42,432
Long term investments
(27,632)
Excess cash
45,109
17,006
33,013
Stockholders' equity
39,016
59,150
46,685
Invested Capital
131,583
151,668
126,448
ROIC
51.79%
ROCE
43.65%
EV
Common stock shares outstanding
29,937
32,962
34,245
Price
1.11
-32.32%
1.64
-76.33%
6.93
-35.47%
Market cap
33,230
-38.53%
54,061
-77.22%
237,316
-33.65%
EV
(12,291)
34,366
197,220
EBITDA
(3,961)
3,750
73,853
EV/EBITDA
3.10
9.16
2.67
Interest
152
171
227
Interest/NOPBT
0.31%